Prabhudas Lilladher's research report on Aster DM Healthcare
ASTER DM Healthcare’s (ASTERDM) Q1 consolidated EBITDA grew 25% YoY to Rs2.1bn, 6% above our estimate. EBITDA beat was led by improved performance at Kerala cluster. EBITDA has been increasing sharply over the last 3 years (29% CAGR over FY22-25). Our FY26-27E EBITDA estimate broadly remains unchanged. We estimate 24% EBITDA CAGR over FY25-27E aided by scale-up in margins, healthy ARPOB and bed additions. ASTERDM’s board has recently approved merger with Quality Care (QCIL), making it the third largest healthcare chain by revenue and bed capacity in India. The combined entity is trading at ~26x EV/EBITDA on FY27E (adj for minority stake and rental).
Outlook
We maintain our BUY rating with a revised TP of Rs700/share, valuing 30x EV/EBITDA for combined entity.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
